India's pharmaceutical manufacturing sector is entering an important procurement transition as the temporary customs duty waiver on several imported polymer products comes to an end. The policy had provided cost relief during a period of elevated global petrochemical prices, helping manufacturers secure essential packaging materials for medicines, medical devices, and healthcare products.
Although international polymer prices have eased compared with the peak levels seen earlier in 2026, the expiry of the duty exemption changes the overall cost structure for pharmaceutical packaging manufacturers. Procurement teams must now reassess sourcing strategies, supplier contracts, inventory planning, and cost forecasts to maintain competitiveness while ensuring uninterrupted production.
Why the Duty Waiver Was Important
The temporary customs duty exemption helped pharmaceutical manufacturers reduce production costs during a period of volatile global chemical markets.
The waiver supported procurement of:
Medical-grade polymers
Packaging resins
Plastic processing materials
Medical device components
Healthcare packaging inputs
For many manufacturers, lower import duties partially offset higher international resin prices and increased freight costs.
Medical-Grade Polymers Remain Essential
Modern pharmaceutical packaging depends on specialized polymers that meet strict regulatory and quality requirements.
The most widely used materials include:
Polypropylene (PP)
Used for:
Syringe barrels
Medicine containers
Sample collection tubes
Laboratory consumables
PP Homopolymer J170H (Injection) - South Korea CAS: 9003-07-0
Polycarbonate (PC)
Common applications include:
IV connectors
Medical device housings
Diagnostic equipment
Transparent medical components
Medical Grade PVC
Widely used for:
IV tubing
Blood bags
Catheters
Flexible medical packaging
Each material offers specific performance characteristics required for pharmaceutical applications.
Procurement Costs Require Reassessment
With the duty waiver ending, procurement teams should evaluate the total landed cost of imported packaging materials.
Important cost considerations include:
Import duties
Freight charges
Currency fluctuations
Warehousing costs
Customs clearance
Domestic transportation
A comprehensive cost analysis helps companies make informed sourcing decisions.
Inventory Planning Becomes More Important
Manufacturers should review inventory strategies to avoid unnecessary cost increases.
Recommended actions include:
Assess current stock levels.
Review safety stock policies.
Forecast Q3 packaging demand.
Coordinate purchasing with production schedules.
Reduce emergency procurement.
Monitor supplier lead times.
Proper inventory planning can help offset some of the financial impact of higher import costs.
Supplier Diversification Reduces Procurement Risk
Relying on a single supplier or sourcing region can expose manufacturers to pricing and supply disruptions.
Best practices include:
Qualify multiple polymer suppliers.
Source from different countries.
Maintain approved backup vendors.
Compare regional pricing regularly.
Review supplier production capacity.
Monitor supplier financial stability.
Supplier diversification improves both supply continuity and commercial flexibility.
Sustainability Continues to Influence Packaging
Even as procurement teams focus on costs, sustainability remains an important purchasing consideration.
Growing industry priorities include:
Recyclable packaging
Reduced plastic usage
Lightweight packaging designs
Improved material efficiency
Regulatory compliance
Sustainable resin alternatives
Many pharmaceutical companies continue integrating sustainability objectives into procurement decisions.
Quality and Regulatory Compliance Remain Critical
Cost optimization should never compromise product quality.
Packaging suppliers should continue providing:
Regulatory certifications
Material traceability
Batch consistency
Migration testing reports
Pharmacopoeia compliance
Quality management documentation
Maintaining regulatory compliance protects both product quality and patient safety.
Procurement Strategy for Q3 2026
As the market adjusts to the new cost environment, pharmaceutical packaging manufacturers should adopt a balanced procurement strategy.
Recommended priorities include:
Request updated supplier quotations.
Compare domestic and imported materials.
Negotiate medium-term supply agreements.
Monitor polymer market trends.
Review freight costs regularly.
Strengthen supplier relationships.
Companies that combine disciplined purchasing with diversified sourcing will be better positioned throughout the remainder of 2026.
Market Outlook
India's pharmaceutical packaging industry is expected to remain strong during the second half of 2026 despite the expiry of the customs duty waiver. Lower international polymer prices should partially offset the impact of higher import duties, limiting overall cost increases for many manufacturers. Demand for medical packaging materials will continue to grow alongside expanding pharmaceutical production and healthcare investment.
Looking ahead, procurement teams should focus on total cost optimization rather than purchasing price alone. Supplier diversification, efficient inventory management, quality assurance, and long-term commercial partnerships will remain essential for maintaining reliable packaging supply while controlling procurement costs.
Key Takeaways
India's pharmaceutical packaging cost structure changes following the duty waiver expiry.
Medical-grade polymers remain essential for pharmaceutical manufacturing.
Procurement teams should evaluate total landed costs instead of material prices alone.
Inventory planning helps reduce exposure to future price volatility.
Supplier diversification strengthens long-term supply security.
Quality and regulatory compliance remain top procurement priorities.
Sustainable packaging continues gaining importance across the pharmaceutical industry.
Strategic sourcing will help manufacturers manage costs throughout H2 2026.
